
Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

Transine Therapeutics Ltd closes £13.7m seed financing
Transine Therapeutics stressed it will use the proceeds to accelerate its preclinical pipeline of novel therapeutic RNAs (SINEUPs) capable of...

Single-use market to reach $20.8bn by 2026
The "Global Forecast 2026" comprises Media Bags and containers, Bioreactors, Mixers, Assemblies, Applications (Cell Culture, Mixing,...

TWB announces winners in industrial biotech start-up contest
Hosted for the fifth time by Toulouse White Biotechnology, the TWB Start-up Day showcased what industrial biotechnology can already do today to...

International Vaccine Institute – IVI – will locate its European office in Stockholm
The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified...

GSK acquires Sierra Oncology for 1.9bn
GSK is paying $1.9 bn in cash ($55 per share) for the deal. This is a 39 per cent premium to the Sierra share price on 12 April and a 63 per cent...